At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 79 enrolled
Drug / intervention
CF101 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase IIB Study of the Efficacy and Safety of Daily CF101 in Patients With Active Rheumatoid Arthritis and Elevated Baseline Expression Levels of Peripheral Blood Mononuclear Cell A3 Adenosine Receptors
In Brief
A Phase 2 clinical trial evaluating CF101 and Placebo control for Rheumatoid Arthritis. Completed, enrolled 79 participants across 5 sites in 2 countries.
Detailed Summary
This trial will test the hypothesis that the administration of CF101, a novel anti-inflammatory agent, to patients with rheumatoid arthritis and high A3AR expression at baseline will relieve signs and symptoms of the disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesBulgaria, Israel
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 2009
Enrollment StartOct 2010
Primary CompletionDec 2013
TodayJul 2026
First PostedDec 17, 2009
Enrollment StartOct 1, 2010
Primary CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 16.5 years ago
Interventions
CF101drug
orally q12h
Placebo controldrug
orally q12 hours